WINDLAS

Windlas Biotech Share Price

₹946.75 -9.9 (-1.03%)

19 May, 2025 20:59

SIP TrendupStart SIP in WINDLAS

Start SIP

Performance

  • Low
  • ₹935
  • High
  • ₹974
  • 52 Week Low
  • ₹534
  • 52 Week High
  • ₹1,198
  • Open Price₹960
  • Previous Close₹957
  • Volume44,711

Investment Returns

  • Over 1 Month -12.67%
  • Over 3 Month + 29.71%
  • Over 6 Month -3.8%
  • Over 1 Year + 71.17%
SIP Lightning

Smart Investing Starts Here Start SIP with Windlas Biotech for Steady Growth!

Invest Now

Windlas Biotech Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 32.2
  • PEG Ratio
  • 1.9
  • Market Cap Cr
  • 1,984
  • P/B Ratio
  • 4.2
  • Average True Range
  • 52.68
  • EPS
  • 29.52
  • Dividend Yield
  • 0.6
  • MACD Signal
  • 3.77
  • RSI
  • 42.72
  • MFI
  • 32.34

Windlas Biotech Financials

Windlas Biotech Technicals

EMA & SMA

Current Price
₹946.75
-9.9 (-1.03%)
pointer
  • stock-down_img
  • Bearish Moving Average 15
  • stock-up_img
  • Bullish Moving Average 1
  • 20 Day
  • ₹983.15
  • 50 Day
  • ₹972.62
  • 100 Day
  • ₹958.86
  • 200 Day
  • ₹903.53

Resistance and Support

952.07 Pivot Speed
  • R3 1,008.58
  • R2 991.52
  • R1 969.13
  • S1 929.68
  • S2 912.62
  • S3 890.23

What's your outlook on Windlas Biotech?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Windlas Biotech Ltd. is a pharmaceutical company specializing in contract development and manufacturing, producing a wide range of formulations, including tablets, capsules, and syrups. It serves both domestic and international markets with quality, affordable healthcare solutions.

Windlas Biotech has an operating revenue of Rs. 728.46 Cr. on a trailing 12-month basis. An annual revenue growth of 23% is outstanding, Pre-tax margin of 12% is healthy, ROE of 12% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its 50DMA and close to its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 75 which is a FAIR score but needs to improve its earnings, a RS Rating of 86 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at B which is evident from recent demand for the stock, Group Rank of 51 indicates it belongs to a fair industry group of Medical-Ethical Drugs and a Master Score of B is close to being the best. Overall, the stock is lagging behind in earnings parameter, but excellent technical strength makes it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Windlas Biotech Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-05-22 Audited Results & Final Dividend
2025-02-11 Quarterly Results
2024-11-12 Quarterly Results
2024-08-13 Quarterly Results
2024-05-20 Audited Results & Dividend

Windlas Biotech F&O

Windlas Biotech Shareholding Pattern

62.34%
6.7%
1.52%
21.36%
8.08%

About Windlas Biotech

  • NSE Symbol
  • WINDLAS
  • BSE Symbol
  • 543329
  • Managing Director
  • Mr. Hitesh Windlass
  • ISIN
  • INE0H5O01029

Similar Stocks to Windlas Biotech

Windlas Biotech FAQs

Windlas Biotech share price is ₹946 As on 19 May, 2025 | 20:45

The Market Cap of Windlas Biotech is ₹1984.3 Cr As on 19 May, 2025 | 20:45

The P/E ratio of Windlas Biotech is 32.2 As on 19 May, 2025 | 20:45

The PB ratio of Windlas Biotech is 4.2 As on 19 May, 2025 | 20:45

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23